Our capabilities and experience
Read more about how we help manage complex clinical research across many therapeutic areas worldwide.
Page 4 of 6
Celebrating Our 2-Year Anniversary
We’re proud of our progress and remain committed to and passionate about our mission-driven work globally.
Phase II Trial of a Chikungunya Vaccine in the Caribbean
The study team maintained a 91% retention rate in a study of a Chikungunya virus (CHIKV) vaccine, despite study disruptions due to natural disasters, including Hurricane Maria, and political unrest near the sites in five Caribbean countries in a CHIKV endemic region.
How Can We Streamline the Vaccine Development Process?
To address the urgency of vaccine development during a pandemic, innovative strategies are implemented across study design, regulatory processes, recruitment process and more. In this e-book, we describe some of those innovations and argue for incorporating these into the fabric of clinical trials — to establish a “new normal.”
Site Monitoring & Management in a Clinical Trial of a Spatial Repellent for Vector-Borne Disease Control
The FHI Clinical project team supported site monitoring, site management and project management to assist the University of Notre Dame investigators achieve a level of rigor not typically required for a non-medical product in their double-blinded, randomized-cluster, placebo-controlled clinical trial of a spatial repellent against mosquitoes for malaria prevention.
Our Clinical Trial Experience With Ebola Virus Disease
Since 1976, Ebola virus disease outbreaks have primarily occurred in eleven countries: Democratic Republic of the Congo, Gabon, Guinea, Liberia, Mali, Nigeria, Republic of Congo, Sierra Leone, Sudan and Uganda. Although it is generally rare, it is often fatal, with death rates ranging from 25 to 90% in past outbreaks (average case fatality rate, 50%). No treatment or vaccine is currently approved, but there are several promising vaccines and treatments under development.
Successful Outbreak Responses Depend On Reliable Data
In this webinar, industry veterans Michelle Berrey, MD, MPH, and Claudia Christian discuss the importance of quality data for a successful outbreak response plan.
Dengue Fever Fact Sheet
Dengue fever, a mosquito-borne tropical disease, is the most common and important arthropod-borne (arboviral) illness in humans. It is caused by four serotypes of the dengue virus, of which more than one can circulate during an epidemic. Infection with one serotype confers lifelong homotypic immunity to that serotype and a brief period (~2 years) of partial heterotypic immunity to other serotypes. However, an individual can eventually be infected by all four serotypes.
8 Key Lessons for Outbreak Responses
Outbreaks large and small require rapid, coordinated responses. In this infographic, we describe eight considerations for outbreak responses, based on the collective experience of our experts.
Rapid Site Assessment and Recommendations for Clinical Trials of a New Malaria Treatment
Targeted geographic areas for the development of an antimalarial drug by Novartis included malaria-endemic regions in Africa and Asia, and Novartis requested assistance identifying and assessing potential clinical sites for their planned clinical trial. Our team conducted 38 rapid, in-depth, 2.5-day site feasibility assessments in the 18 countries.
What Can We Learn From Past Outbreaks?
Outbreaks large and small require rapid, coordinated responses. In this e-book, we describe eight considerations for outbreak responses, based on the collective experience of our experts.
